HYDERABAD/BENGALURU (Reuters) – Sun Pharmaceuticals, India’s largest drugmaker by revenue, reported second-quarter profit above analysts’ estimates on Monday, aided by strong sales of its specialty drugs that are used to treat uncommon medical conditions.
The Mumbai-based firm’s net profit rose 28% to 30.40 billion rupees (nearly $362 million) in the three months ended Sept. 30, beating analysts’ average estimate of 28.87 billion rupees, according to LSEG data.
($1 = 84.0510 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Sumana Nandy and Rashmi Aich)
Comments